Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Marcus Koch

doi:10.1136/jnnp-2023-332758

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF

Editorial commentary

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Free

Online download statistics by month:

Online download statistics by month: November 2023 to October 2024

	Abstract	Full	Pdf
Nov 2023	606	600	116
Dec 2023	370	367	66
Jan 2024	315	310	30
Feb 2024	249	249	38
Mar 2024	231	233	29
Apr 2024	997	1004	61
May 2024	690	698	53
Jun 2024	64	64	26
Jul 2024	64	64	19
Aug 2024	50	51	25
Sep 2024	45	46	21
Oct 2024	52	50	24
Total	3733	3736	508

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: November 2023 to October 2024

Read the full text or download the PDF:

Log in using your username and password